AddTweet Post to Facebook hEmail this
‹‹ Go Back

Michael F. Weaver, MD, DFASAM

Professor and Medical Director, Center for Neurobehavioral Research on Addiction, University of Texas McGovern Medical School at Houston, Houston, Texas

presenter photoDr. Michael Weaver is Professor of Psychiatry and Medical Director of the Center for Neurobehavioral Research on Addiction at The University of Texas McGovern Medical School at Houston. He completed a Residency in Internal Medicine and a Clinical Research Fellowship in Addiction Medicine at Virginia Commonwealth University. He is involved in patient care, medical education, and research. Dr. Weaver has multiple publications in the field of addiction medicine. He treats patients at the Innovations Addiction Treatment Clinic at the Texas Medical Center in Houston, which provides medication-assisted treatment. He is the Chair of the Examination Committee for the American Board of Addiction Medicine, as well as serving on the Maintenance of Certification Committee. He is a member of the ASAM Publications Council and on the Editorial Board for the Journal of Addiction Medicine.

‹‹ Go Back

John A. Hopper, MD, FASAM

Program Director, Internal Medicine Residency, St. Joseph Mercy Hospital, Ypsilanti, Michigan

presenter photoDr. Hopper attended Medical School at Wayne State University and completed his residency in Combined Internal Medicine and Pediatrics at the University of North Carolina, where he served as Co-Chief Resident in Pediatrics. Dr. Hopper was appointed to the faculty at Wayne State University School of Medicine in 1994 where he served as Associate Program Director for the Med-Peds Residency and Medical Director of the Department of Psychiatry’s Research Division on Substance Abuse. From 2005 to 2008, he was the Chief Medical Officer at Brighton Hospital, the second oldest addiction treatment hospital in the United States. In addition to his many clinical and teaching awards, Dr. Hopper serves on the Editorial Board of the Journal of Opioid Management. Since 2008 Dr. Hopper has directed the Internal Medicine Residency Program at St. Joseph Mercy Hospital in Ann Arbor, Michigan. In 2013 Dr. Hopper started Michigan’s first American Board of Addiction Medicine approved addiction fellowship.

‹‹ Go Back

Erik W. Gunderson, MD, FASAM

Medical Director, Center for Wellness and Change, University of Virginia, Charlottesville, Virginia



‹‹ Go Back

Please enter your access key

The asset you are trying to access is locked for premium users. Please enter your access key to unlock.


Email This Presentation:

From:

To:

Subject:

Body:

Focus Session Track

Designer Drugs Update 2015: Bath Salts, Spice, and N-bomb

4/25/2015

2:30 PM - 3:30 PM

Room: 412, Fourth Floor

Organizer (Presenting)(s):

Michael F. Weaver, MD, DFASAM

Professor and Medical Director, Center for Neurobehavioral Research on Addiction, University of Texas McGovern Medical School at Houston, Houston, Texas

Presenter(s):

John A. Hopper, MD, FASAM

Program Director, Internal Medicine Residency, St. Joseph Mercy Hospital, Ypsilanti, Michigan

Erik W. Gunderson, MD, FASAM

Medical Director, Center for Wellness and Change, University of Virginia, Charlottesville, Virginia

Patterns of drug abuse are constantly changing. This is particularly the case regarding new psychoactive substances or designer drugs, in which new variants are continually emerging with uptake especially among young adults. New synthetic designer drugs can be challenging to identify and treat effectively, especially serious medical and psychiatric complications. This is important for practitioners, as new designer drugs have resulted in multiple deaths, as well as other significant health consequences to users. This session will educate practitioners about several newer designer drugs regarding use trends along with psychotropic and health effects.Attendees will be provided with evidence-based clinical knowledge to help identify and treat complications from newer designer drug use, especially those with life-threatening complications. Attendees will have the opportunity to participate in an evidence-based discussion—including clinical case examples—that will focus on emerging designer drugs, including cathinones (bath salts), synthetic cannabinoids (spice), and synthetic hallucinogens (N-bomb). The emphasis will be on clinical issues, especially recognition of intoxication, problems related to detection with urine drug testing, and treatment of medical and psychiatric complications.